RESULTS: VATS resection was performed in 271 patients (24.9%) and open surgery in 816 patients (75.1%). Before propensity score matching, the VATS group had a smaller tumour size (P = 0.002), lower grade histology (P = 0.034), lower T stage (P < 0.001) and less adjuvant therapy (P < 0.001). Propensity score matching by gender, myasthenia gravis, tumour size, histological classification, pathological T stage, extent of thymectomy, adjuvant radiotherapy and adjuvant chemotherapy identified 110 patients in each group. After matching, there was no significant difference in patient demographics, tumour characteristics or adjuvant therapy. All matched patients had R0 resection. Overall survival, disease-free survival and cumulative incidence of recurrence were only predicted by WHO histology, but not by surgical approach, in both univariable and multivariable analyses. There was no significant difference in the overall survival (85.7% vs 93.1%, P = 0.539), disease-free survival (92.5% vs 91.9%, P = 0.773), cumulative incidence of recurrence (7.1% vs 5.8%, P = 0.522) and improvement rate of myasthenia gravis (83.3% vs 88.2%, P = 0.589) between the 2 groups. CONCLUSIONS: This propensity score-matched study suggests that VATS and open surgeries are associated with similar oncological outcomes for Stage I thymic epithelial tumours. Minimally invasive surgery might be an acceptable surgical approach for early-stage thymic malignancies.
INTRODUCTION
Median sternotomy has been the standard approach for surgical management of thymic epithelial tumours. However, the last decade has seen increasing adoption of video-assisted thoracoscopic surgery (VATS) for thymectomy. By avoiding sternal split, rib spread or muscle division, VATS thymectomy (VT) has been reported to have advantages over open thymectomy (OT), including lower operative blood loss, less drainage and pain after surgery, shorter hospital stays, improved postoperative pulmonary function and better quality of life [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Despite this growing interest in VT, there have been no controlled studies comparing the efficacy of VT to OT, with the majority of studies focusing on perioperative rather than oncological outcomes [14, 15] . Most of the existing studies are single-centre retrospective series with a small number of cases, with the only exception of 3 global or regional cooperation reports very recently published by the International Thymic Malignancy Interest Group (ITMIG), the Japanese Association for Research on the Thymus (JART) and the Chinese Alliance for Research in Thymomas (ChART), respectively [16] [17] [18] . In addition, current clinical guidelines do not recommend a minimally invasive surgery as a routine procedure for the reason of lack of powerful clinical research evidence [19] .
In this study, we aimed to examine oncological outcomes in a large group of patients with pathology Stage I thymic tumours and who have undergone thymectomy through either VATS or an open approach. To minimize selection bias, we performed a propensity score-matched analysis to generate 2 homogenous groups for comparison.
MATERIALS AND METHODS
The ChART database, which uses the same datasheet of the ITMIG global database, is a multi-institutional retrospective database with contributions from 18 tertiary referral centres in China during 1994-2012 [20] . Informed consent was waived by an institutional review board because of the retrospective nature of the study, and only deidentified data were used for this analysis. Tumour stage was re-reclassified according to the International Association for the Study of Lung Cancer and International Thymic Malignancy Interest Group (IASLC/ITMIG) TNM staging proposal [21] , and the histological typing of the tumours was classified according to the World Health Organization (WHO) 2004 Classification of Thymoma [22] . Preoperative classification and the result evaluation of patients with myasthenia gravis (MG) were performed according to both the Myasthenia Gravis Foundation of America Clinical Classification and PostIntervention Status [23] . For this project, OT was defined as either sternotomy or thoracotomy. In addition, transcervical resection was intentionally excluded as it represented a minority of resection type. Conversion from VT to OT incision data was not available from the retrospective ChART database. A total thymectomy was defined in the database as resection of the tumour together with the thymus gland, whereas a partial thymectomy was defined as resection of the tumour with a margin of normal thymic tissue. The R0, R1 and R2 variables were defined in the database as being identified from pathology reports.
Inclusion criteria for the current study were pathological Stage I thymic tumours surgically resected via either OT or VT. Exclusion criteria included cases receiving neoadjuvant therapy or no surgical treatment. In addition, cases lacking detailed information on histology, staging or surgical approach were removed from the study (Fig. 1) .
Statistical analysis was performed using the SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Patient characteristics were compared between the VT and OT groups. Categorical variables were analysed using the v 2 test or the Fisher's exact test for small samples, for differences between the groups. Continuous data were compared using the Student's t-test. To investigate the differences between the groups while reducing the effects of confounding, a 1:1 propensity matching was performed. In addition to covariates with significant difference between the 2 groups, factors considered potentially related to the long-term outcomes were also included in propensity score matching, leaving 8 covariates including gender, myasthenia gravis, tumour size, histological classification, pathological T stage, extent of thymectomy, adjuvant radiotherapy and adjuvant chemotherapy. The patients undergoing VT were ordered and sequentially matched to the nearest unmatched patients undergoing OT. Kaplan-Meier survival curves were constructed, and survival difference was compared using the log-rank test. To assess the impact of potential risk factors on survival and recurrence, univariable analysis was performed using the Cox univariate model. Multivariable analysis was performed with a Cox proportional hazard model, using the backwards step-down method. Entry and removal limits were P-value = 0.2 and 0.25, respectively. Statistical significance was accepted as a P-value of <0.05 throughout the study.
RESULTS
In the ChART retrospective database, VT was first used in 2004, as shown in Fig. 2 . A sharp increase could be seen in the later 3 years to over 30% by the end of the study cohort. A total of 1087 patients were enrolled in this study, and their demographic and tumour characteristics are presented in Table 1 . VT was performed in 271 patients (24.9%) and OT in 816 patients (75.1%).
A propensity score graph of the variables was shown in the Supplementary Material. Before matching, 88.9% (16/18) of institutions were enrolled in this study. After matching, 44.4% (8/18) were excluded. No significant difference was observed in age, proportion of patients with MG, complete (R0) resection or extent of thymectomy between the 2 groups before matching. There were more females in the VT group than in the OT group but only with a borderline significance (P = 0.051). Patients who underwent VT had more favourable WHO histological types and less advanced pathological T stage than that of patients who underwent OT. Mean tumour size was smaller in the VT group when compared with the OT group (P = 0.002). Patients in the VT group were less likely to have adjuvant therapies than those in the OT group (P < 0.001). After matching, however, the differences in patient gender, tumour size, histology type, T stage and adjuvant therapy were no longer statistically significant (Table 2) . Median follow-up time was 26 and 36 months for VT and OT, respectively. All matched patients had R0 resection ( Table 2 ). The recurrence rate was similar in the VT group compared with the OT group (1% vs 3.8%, P = 0.369). In the VT group, only 1 patient had local recurrence. In the OT group, 1 patient had local recurrence, 2 patients had pleura dissemination and 1 patient had lung metastasis. The improvement rate of MG was similar between the 2 matched groups (83.3% vs 88.2%, P = 0.589), and there was no significant difference in overall survival (OS, 85.7% vs 93.1%, P = 0.539), disease-free survival (DFS, 92.5% vs 91.9%, P = 0.773) or cumulative incidence of recurrence (CIR, 7.1% vs 5.8%, P = 0.522) between the 2 matched groups (Fig. 3) . In univariable and multivariable analyses, only WHO classification was associated with OS, DFS and CIR (Tables 3-5 ).
DISCUSSION
In this study, using the ChART retrospective database patients with pathology Stage I thymic tumours, including both thymomas and thymic carcinomas, operated on via VATS had similar oncological outcomes compared to those via open surgery. Of note, we found that only WHO histology types, but not surgical approach, predicted long-term prognosis in early-stage tumours.
In recent years, there has been a noticeable trend towards minimally invasive surgery for thymectomy worldwide. Both the ITMIG and the ChART retrospective studies showed a sharp increase in VT since 2010 [16, 18] . Many studies have shown superior perioperative results of VT in terms of less operative blood loss, decreased postoperative pain, shortened hospital stays, improved postoperative pulmonary function and better quality of life after surgery [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . However, it is equally important to prove the oncological efficacy of minimally invasive procedures before they could be routinely recommended by the guidelines. Although some studies reported similar resection rates and OSs between the VT and OT groups [1, 2, 6, [10] [11] [12] , most of them were small-sized, monocentric, non-randomized retrospective studies or even lacked long-term follow-up data. In addition, almost all of them failed to take into account inherent biases in patient selection, including tumour stage, histology and adjuvant therapies, which may greatly influence the study results. Therefore, we attempted to minimize selection bias by limiting our initial analysis to only patients with pathology Stage I tumours in this study. In addition, because tumour stage, histology and adjuvant therapies are critical determinants of the long-term outcomes, we controlled for these variables by performing propensity score matching.
Complete tumour resection has been considered a critically important indicator for oncological outcomes in thymic malignancies as resection status is closely associated with survival and recurrence [24] . Through meta-analyses, Friedant et al. [14] found that there was no difference between VATS or open surgery in R0 resection rate [n = 711, 97.36% vs 97.25%, odds ratio = 0.98, 95% confidence interval 0.23-4.14; P = 0.88] or locoregional recurrence rate (n = 234, 2.86% vs 2.91%, Incidence rate ratios = 2.10, 95% CI 0.39-11.25, P = 0.39) in patients with Masaoka Stage I or II thymic tumours, including thymic carcinoma. The recently published ITMIG retrospective study also reported that R0 resection of thymoma could be achieved at comparable rates by minimally invasive or OT in all tumour stages after propensity score matching (96% vs 96%, P = 0.7), and a surgical approach was not a predictor of R0 resection in multivariate analysis [16] . In our study, R0 resection rate was similar between the VT and OT groups before matching, and it was 100% in each group in matched analyses. It is thus reasonable to assume that early-stage thymic tumours could be managed via minimally invasive surgery due to its feasibility to remove the disease completely, and therefore, to achieve satisfactory oncological outcomes.
Our results also showed that after matching with demographic and tumoural characteristics, both OS (85.7% vs 93.1%, P = 0.539) and DFS (92.5% vs 91.9%, P = 0.773) as well as CIR (7.1% vs 5.8%, P = 0.522) were comparable after the 2 procedures. In a previous study, also using the ChART retrospective database, the same authors found comparable OS (92% vs 92%, P = 0.15), less recurrence (2.9% vs 16.0%, P = 0.000) and better DFS (92% vs 83%, P = 0.011) after VATS than after OT among 1117 patients with clinical Masaoka-Koga Stage I-II TETs. The results were in accordance with most retrospective studies using non-matched patient cohorts in that patients with lower-risk tumours were more likely to be selected to receive VATS resection, although we did not find any difference in the incidence of recurrence (3.3% vs 4.7%, P = 0.579) by a subgroup analysis of pathological Masaoka-Koga Stage I and II patients [18] . In the current study, the VT group also had smaller tumour size (P = 0.002), lower grade histology (P = 0.034), lower T stage (P < 0.001) and less adjuvant therapy (P < 0.001), when compared with the OT group before propensity score matching. The potential selection bias in the previous and current studies has prompted us to carry out this propensity score-matched analysis to further examine the prognosis of patients with early-stage thymic tumours. By minimizing selection bias through a more carefully designed study, our current results are even more persuasive in showing that oncological outcomes after VT for UICC stage I tumors are at least non-inferior to OT. The recently published Japanese study by Agatsuma et al. [17] also showed that VT was a safe and feasible procedure for thymic tumours with similar oncological outcomes and postoperative complication rates when compared with sternotomy. However, in that study, only sternotomy was used as the control approach, while both sternotomy and lateral thoracotomy were included in the current series. Although both studies used propensity score matching with the intention to minimize the potential confounding biases, matching covariates were not described in detail in the Japanese study, leaving significantly less patients receiving extended thymectomy in the VATS group. In addition, patients with preoperative chemotherapy or radiation were still included in the sternotomy group, while no such patient was found in the VATS group after matching. In the current study, no patient with preoperative induction therapy was included, and all factors potentially associated with oncological outcomes were carefully matched, including both resection extent and adjuvant therapies. Moreover, only thymoma patients were included in the Japanese study, while both thymoma and thymic carcinoma patients were studied in our series. As it is highly unlikely to determine tumour histology before surgery, especially in early-stage diseases, our results indicate that minimally invasive surgery could be applied similarly in all early-stage thymic tumours irrespective of histology as long as similar surgical and oncological principles are observed.
Tumour stage, histology and resection status have been considered the 3 most important prognostic factors for thymic malignancies [20] . Our study showed that only the WHO classification was associated with OS, DFS and CIR in both univariable and multivariable analyses. This was not surprising as all patients in the current study had UICC Stage I tumours and all had R0 resection in the matched groups, thus leaving tumour histology as the only remaining prognostic factor. In this homogenous group of patients, the WHO classification was the only predictor of oncology outcomes with thymic carcinoma and neuroendocrine tumours carrying a more than 10-fold higher risk for worse OS [hazard ratio = 15.504, 95% CI 1.4-171.148; P = 0.025] and DFS (HR = 13.636, 95% CI 1.555-119.546; P = 0.018) and 20-fold higher risk for tumour recurrence (HR = 23.32, 95% CI 1.672-325.31; P = 0.019). In fact, UICC Stage I (as equal to Masaoka Stages I and II) tumours could be readily resected by either VATS or open surgery. The long-term prognosis would depend mostly on the nature of the disease. It is quite unlikely that the surgical approach would make a significant difference as long as the lesion could be completely removed and similar oncological principles be observed during surgery. 
Limitations
Although still retrospective in nature, the main strength of our study is that it was based on one of the largest thymic malignancy databases ever collected. Furthermore, the participating institutions used a uniform staging system and histological classification. As such, a more homogenous group of patients were selected for subanalysis after propensity score matching, which helps to avoid confounding biases to the greatest possible extent. Nonetheless, it still has its limitations in that it is not equivalent to a prospective study. But given the relatively indolent behaviour of thymic tumours, thousands of cases would be needed for a controlled randomized trial, which is basically impossible for such a rare disease. We also acknowledge some missing data in the ChART database, for example, incomplete data on the recurrent sites. It is unclear whether VT may increase the risk of pleura implantation. In addition, median follow-up time was shorter in the VT group as many patients in this group were operated on at a later period. The longer follow-up is necessary as thymic tumours are relatively indolent in nature and recurrence may develop years later, although it is less likely to affect the OS of the patients.
CONCLUSION
In conclusion, this propensity score-matched study suggests that VATS and open surgeries are associated with similar oncological outcomes for UICC Stage I thymic tumours, including both thymoma and thymic carcinoma. Given the superior perioperative results after minimally invasive thymectomy, it should be considered as an acceptable approach and thus be recommended for the surgical management of earlystage thymic malignancies. 
